SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3nwa'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1N4F_A_ASRA140_0 (LYSOZYME C)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	3 / 3	ASN B 108 ALA B 111 ASN B 621	None	0.82A	1n4fA-3nwaB: undetectable	1n4fA-3nwaB: 10.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XVA_B_SAMB293_0 (GLYCINE N-METHYLTRANSFERASE)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 12	ALA B 390 SER B 388 ARG B 377 TYR B 429 TYR B 452	None	1.23A	1xvaB-3nwaB: undetectable	1xvaB-3nwaB: 16.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2F16_K_BO2K1402_1 (PROTEASOME COMPONENT PRE2 PROTEASOME COMPONENT C5)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.96A	2f16K-3nwaB: undetectable 2f16L-3nwaB: undetectable	2f16K-3nwaB: 13.95 2f16L-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2F16_Y_BO2Y1403_1 (PROTEASOME COMPONENT PRE2 PROTEASOME COMPONENT C5)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.94A	2f16Y-3nwaB: undetectable 2f16Z-3nwaB: undetectable	2f16Y-3nwaB: 13.95 2f16Z-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WQ5_A_MIYA1120_1 (PHOSPHOLIPASE A2, ACIDIC)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	4 / 7	LEU B 449 GLY B 414 ARG B 418 PHE B 150	None	0.89A	2wq5A-3nwaB: undetectable	2wq5A-3nwaB: 12.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3B0W_B_DGXB1_2 (NUCLEAR RECEPTOR ROR-GAMMA)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	3 / 3	LEU B 330 VAL B 276 ARG B 245	None	0.70A	3b0wB-3nwaB: undetectable	3b0wB-3nwaB: 14.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MG0_K_BO2K1402_1 (PROTEASOME COMPONENT PRE2 PROTEASOME COMPONENT C5)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	3mg0K-3nwaB: undetectable 3mg0L-3nwaB: undetectable	3mg0K-3nwaB: 13.95 3mg0L-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3R24_A_SAMA302_1 (2'-O-METHYL TRANSFERASE)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	3 / 3	TYR B 213 ASP B 167 ASP B 188	None	0.81A	3r24A-3nwaB: undetectable	3r24A-3nwaB: 18.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG8_A_IMNA2001_2 (ALDO-KETO REDUCTASE FAMILY 1 MEMBER C3)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	3 / 3	TYR B 301 GLU B 286 TYR B 296	None	0.97A	3ug8A-3nwaB: undetectable	3ug8A-3nwaB: 17.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CLA_A_CLMA221_0 (TYPE III CHLORAMPHENICOL ACETYLTRANSFERASE)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	THR B 394 ALA B 504 PHE B 503 SER B 387 ILE B 450	None	1.38A	4claA-3nwaB: undetectable	4claA-3nwaB: 13.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4EJG_B_NCTB501_1 (CYTOCHROME P450 2A13)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	4 / 8	ASN B 112 THR B 642 LEU B 617 LEU B 623	None	0.77A	4ejgB-3nwaB: undetectable	4ejgB-3nwaB: 21.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4EYZ_A_CCSA109_0 (CELLULOSOME-RELATED PROTEIN MODULE FROM RUMINOCOCCUS FLAVEFACIENS THAT RESEMBLES PAPAIN-LIKE CYSTEINE PEPTIDASES)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	4 / 8	PHE B 508 ILE B 391 SER B 387 ALA B 147	None	1.02A	4eyzA-3nwaB: undetectable	4eyzA-3nwaB: 14.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4EYZ_B_CCSB109_0 (CELLULOSOME-RELATED PROTEIN MODULE FROM RUMINOCOCCUS FLAVEFACIENS THAT RESEMBLES PAPAIN-LIKE CYSTEINE PEPTIDASES)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	4 / 8	PHE B 508 ILE B 391 SER B 387 ALA B 147	None	1.01A	4eyzB-3nwaB: undetectable	4eyzB-3nwaB: 14.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4G19_D_ACTD302_0 (GLUTATHIONE TRANSFERASE GTE1)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	3 / 3	TYR B 213 PHE B 186 ARG B 215	None	1.14A	4g19D-3nwaB: undetectable	4g19D-3nwaB: 15.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVL_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	4qvlK-3nwaB: undetectable 4qvlL-3nwaB: undetectable	4qvlK-3nwaB: 13.95 4qvlL-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVL_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	4qvlY-3nwaB: undetectable 4qvlZ-3nwaB: undetectable	4qvlY-3nwaB: 13.95 4qvlZ-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVM_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 9	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.96A	4qvmK-3nwaB: undetectable 4qvmL-3nwaB: undetectable	4qvmK-3nwaB: 13.95 4qvmL-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVM_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.96A	4qvmY-3nwaB: undetectable 4qvmZ-3nwaB: undetectable	4qvmY-3nwaB: 13.95 4qvmZ-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 9	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.96A	4qvnK-3nwaB: undetectable 4qvnL-3nwaB: undetectable	4qvnK-3nwaB: 13.95 4qvnL-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 9	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	4qvnY-3nwaB: undetectable 4qvnZ-3nwaB: undetectable	4qvnY-3nwaB: 13.95 4qvnZ-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.96A	4qvpK-3nwaB: undetectable 4qvpL-3nwaB: undetectable	4qvpK-3nwaB: 14.10 4qvpL-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.96A	4qvpY-3nwaB: undetectable 4qvpZ-3nwaB: undetectable	4qvpY-3nwaB: 14.10 4qvpZ-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 9	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.94A	4qvqK-3nwaB: undetectable 4qvqL-3nwaB: undetectable	4qvqK-3nwaB: 13.95 4qvqL-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 9	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.94A	4qvqY-3nwaB: undetectable 4qvqZ-3nwaB: undetectable	4qvqY-3nwaB: 13.95 4qvqZ-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.97A	4qw1K-3nwaB: undetectable 4qw1L-3nwaB: undetectable	4qw1K-3nwaB: 13.95 4qw1L-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.97A	4qw1Y-3nwaB: undetectable 4qw1Z-3nwaB: undetectable	4qw1Y-3nwaB: 13.95 4qw1Z-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW3_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	4qw3K-3nwaB: undetectable 4qw3L-3nwaB: undetectable	4qw3K-3nwaB: 13.95 4qw3L-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW3_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 10	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	4qw3Y-3nwaB: undetectable 4qw3Z-3nwaB: undetectable	4qw3Y-3nwaB: 13.95 4qw3Z-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WOZ_F_MN9F401_0 (N-ACETYLNEURAMINATE LYASE)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	4 / 5	LEU B 330 ASP B 329 TYR B 164 THR B 162	None	1.28A	4wozF-3nwaB: undetectable 4wozH-3nwaB: undetectable	4wozF-3nwaB: 17.95 4wozH-3nwaB: 17.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BXN_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	5bxnK-3nwaB: undetectable 5bxnL-3nwaB: undetectable	5bxnK-3nwaB: 13.95 5bxnL-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BXN_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	5bxnY-3nwaB: undetectable 5bxnZ-3nwaB: undetectable	5bxnY-3nwaB: 13.95 5bxnZ-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5D0X_K_BO2K301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 9	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.95A	5d0xK-3nwaB: undetectable 5d0xL-3nwaB: undetectable	5d0xK-3nwaB: 13.92 5d0xL-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5D0X_Y_BO2Y301_1 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 9	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.94A	5d0xY-3nwaB: undetectable 5d0xZ-3nwaB: undetectable	5d0xY-3nwaB: 13.92 5d0xZ-3nwaB: 15.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5JQ7_B_T0RB705_2 (ENVELOPE GLYCOPROTEIN 2)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	4 / 7	TYR B 164 THR B 351 THR B 346 LEU B 234	None	1.09A	5jq7B-3nwaB: 0.6	5jq7B-3nwaB: 12.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_K_BO2K301_0 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.91A	6hwdK-3nwaB: undetectable 6hwdL-3nwaB: undetectable	6hwdK-3nwaB: 10.17 6hwdL-3nwaB: 7.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_Y_BO2Y301_0 (PROTEASOME SUBUNIT BETA TYPE-5 PROTEASOME SUBUNIT BETA TYPE-6)	3nwa	ENVELOPE GLYCOPROTEIN B (Human alphaherpesvirus 1)	5 / 11	ALA B 211 THR B 221 ALA B 222 ALA B 190 ASP B 188	None	0.91A	6hwdY-3nwaB: undetectable 6hwdZ-3nwaB: undetectable	6hwdY-3nwaB: 10.17 6hwdZ-3nwaB: 7.75

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1N4F_A_ASRA140_0","LYSOZYME C","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",3,"ASN B 108;ALA B 111;ASN B 621","None","0.82A","1n4fA-3nwaB:undetectable","1n4fA-3nwaB:10.09"],["1XVA_B_SAMB293_0","GLYCINE N-METHYLTRANSFERASE","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 390;SER B 388;ARG B 377;TYR B 429;TYR B 452","None","1.23A","1xvaB-3nwaB:undetectable","1xvaB-3nwaB:16.91"],["2F16_K_BO2K1402_1","PROTEASOME COMPONENT PRE2;PROTEASOME COMPONENT C5","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.96A","2f16K-3nwaB:undetectable;2f16L-3nwaB:undetectable","2f16K-3nwaB:13.95;2f16L-3nwaB:15.19"],["2F16_Y_BO2Y1403_1","PROTEASOME COMPONENT PRE2;PROTEASOME COMPONENT C5","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.94A","2f16Y-3nwaB:undetectable;2f16Z-3nwaB:undetectable","2f16Y-3nwaB:13.95;2f16Z-3nwaB:15.19"],["2WQ5_A_MIYA1120_1","PHOSPHOLIPASE A2, ACIDIC","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",4,"LEU B 449;GLY B 414;ARG B 418;PHE B 150","None","0.89A","2wq5A-3nwaB:undetectable","2wq5A-3nwaB:12.02"],["3B0W_B_DGXB1_2","NUCLEAR RECEPTOR ROR-GAMMA","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",3,"LEU B 330;VAL B 276;ARG B 245","None","0.70A","3b0wB-3nwaB:undetectable","3b0wB-3nwaB:14.62"],["3MG0_K_BO2K1402_1","PROTEASOME COMPONENT PRE2;PROTEASOME COMPONENT C5","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","3mg0K-3nwaB:undetectable;3mg0L-3nwaB:undetectable","3mg0K-3nwaB:13.95;3mg0L-3nwaB:15.19"],["3R24_A_SAMA302_1","2'-O-METHYL TRANSFERASE","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",3,"TYR B 213;ASP B 167;ASP B 188","None","0.81A","3r24A-3nwaB:undetectable","3r24A-3nwaB:18.59"],["3UG8_A_IMNA2001_2","ALDO-KETO REDUCTASE FAMILY 1 MEMBER C3","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",3,"TYR B 301;GLU B 286;TYR B 296","None","0.97A","3ug8A-3nwaB:undetectable","3ug8A-3nwaB:17.46"],["4CLA_A_CLMA221_0","TYPE III CHLORAMPHENICOL ACETYLTRANSFERASE","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"THR B 394;ALA B 504;PHE B 503;SER B 387;ILE B 450","None","1.38A","4claA-3nwaB:undetectable","4claA-3nwaB:13.90"],["4EJG_B_NCTB501_1","CYTOCHROME P450 2A13","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",4,"ASN B 112;THR B 642;LEU B 617;LEU B 623","None","0.77A","4ejgB-3nwaB:undetectable","4ejgB-3nwaB:21.11"],["4EYZ_A_CCSA109_0","CELLULOSOME-RELATED PROTEIN MODULE FROM RUMINOCOCCUS FLAVEFACIENS THAT RESEMBLES PAPAIN-LIKE CYSTEINE PEPTIDASES","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",4,"PHE B 508;ILE B 391;SER B 387;ALA B 147","None","1.02A","4eyzA-3nwaB:undetectable","4eyzA-3nwaB:14.75"],["4EYZ_B_CCSB109_0","CELLULOSOME-RELATED PROTEIN MODULE FROM RUMINOCOCCUS FLAVEFACIENS THAT RESEMBLES PAPAIN-LIKE CYSTEINE PEPTIDASES","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",4,"PHE B 508;ILE B 391;SER B 387;ALA B 147","None","1.01A","4eyzB-3nwaB:undetectable","4eyzB-3nwaB:14.75"],["4G19_D_ACTD302_0","GLUTATHIONE TRANSFERASE GTE1","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",3,"TYR B 213;PHE B 186;ARG B 215","None","1.14A","4g19D-3nwaB:undetectable","4g19D-3nwaB:15.54"],["4QVL_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","4qvlK-3nwaB:undetectable;4qvlL-3nwaB:undetectable","4qvlK-3nwaB:13.95;4qvlL-3nwaB:15.19"],["4QVL_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","4qvlY-3nwaB:undetectable;4qvlZ-3nwaB:undetectable","4qvlY-3nwaB:13.95;4qvlZ-3nwaB:15.19"],["4QVM_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.96A","4qvmK-3nwaB:undetectable;4qvmL-3nwaB:undetectable","4qvmK-3nwaB:13.95;4qvmL-3nwaB:15.19"],["4QVM_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.96A","4qvmY-3nwaB:undetectable;4qvmZ-3nwaB:undetectable","4qvmY-3nwaB:13.95;4qvmZ-3nwaB:15.19"],["4QVN_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.96A","4qvnK-3nwaB:undetectable;4qvnL-3nwaB:undetectable","4qvnK-3nwaB:13.95;4qvnL-3nwaB:15.19"],["4QVN_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","4qvnY-3nwaB:undetectable;4qvnZ-3nwaB:undetectable","4qvnY-3nwaB:13.95;4qvnZ-3nwaB:15.19"],["4QVP_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.96A","4qvpK-3nwaB:undetectable;4qvpL-3nwaB:undetectable","4qvpK-3nwaB:14.10;4qvpL-3nwaB:15.19"],["4QVP_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.96A","4qvpY-3nwaB:undetectable;4qvpZ-3nwaB:undetectable","4qvpY-3nwaB:14.10;4qvpZ-3nwaB:15.19"],["4QVQ_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.94A","4qvqK-3nwaB:undetectable;4qvqL-3nwaB:undetectable","4qvqK-3nwaB:13.95;4qvqL-3nwaB:15.19"],["4QVQ_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.94A","4qvqY-3nwaB:undetectable;4qvqZ-3nwaB:undetectable","4qvqY-3nwaB:13.95;4qvqZ-3nwaB:15.19"],["4QW1_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.97A","4qw1K-3nwaB:undetectable;4qw1L-3nwaB:undetectable","4qw1K-3nwaB:13.95;4qw1L-3nwaB:15.19"],["4QW1_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.97A","4qw1Y-3nwaB:undetectable;4qw1Z-3nwaB:undetectable","4qw1Y-3nwaB:13.95;4qw1Z-3nwaB:15.19"],["4QW3_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","4qw3K-3nwaB:undetectable;4qw3L-3nwaB:undetectable","4qw3K-3nwaB:13.95;4qw3L-3nwaB:15.19"],["4QW3_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","4qw3Y-3nwaB:undetectable;4qw3Z-3nwaB:undetectable","4qw3Y-3nwaB:13.95;4qw3Z-3nwaB:15.19"],["4WOZ_F_MN9F401_0","N-ACETYLNEURAMINATE LYASE","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",4,"LEU B 330;ASP B 329;TYR B 164;THR B 162","None","1.28A","4wozF-3nwaB:undetectable;4wozH-3nwaB:undetectable","4wozF-3nwaB:17.95;4wozH-3nwaB:17.95"],["5BXN_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","5bxnK-3nwaB:undetectable;5bxnL-3nwaB:undetectable","5bxnK-3nwaB:13.95;5bxnL-3nwaB:15.19"],["5BXN_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","5bxnY-3nwaB:undetectable;5bxnZ-3nwaB:undetectable","5bxnY-3nwaB:13.95;5bxnZ-3nwaB:15.19"],["5D0X_K_BO2K301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.95A","5d0xK-3nwaB:undetectable;5d0xL-3nwaB:undetectable","5d0xK-3nwaB:13.92;5d0xL-3nwaB:15.19"],["5D0X_Y_BO2Y301_1","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.94A","5d0xY-3nwaB:undetectable;5d0xZ-3nwaB:undetectable","5d0xY-3nwaB:13.92;5d0xZ-3nwaB:15.19"],["5JQ7_B_T0RB705_2","ENVELOPE GLYCOPROTEIN 2","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",4,"TYR B 164;THR B 351;THR B 346;LEU B 234","None","1.09A","5jq7B-3nwaB:0.6","5jq7B-3nwaB:12.27"],["6HWD_K_BO2K301_0","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.91A","6hwdK-3nwaB:undetectable;6hwdL-3nwaB:undetectable","6hwdK-3nwaB:10.17;6hwdL-3nwaB:7.75"],["6HWD_Y_BO2Y301_0","PROTEASOME SUBUNIT BETA TYPE-5;PROTEASOME SUBUNIT BETA TYPE-6","3nwa","ENVELOPE GLYCOPROTEIN B","Human alphaherpesvirus 1",5,"ALA B 211;THR B 221;ALA B 222;ALA B 190;ASP B 188","None","0.91A","6hwdY-3nwaB:undetectable;6hwdZ-3nwaB:undetectable","6hwdY-3nwaB:10.17;6hwdZ-3nwaB:7.75"]]